| Literature DB >> 34960221 |
Fengming Pan1,2, Hongyu Zhao1,2, Stephen Nicholas3,4,5,6, Elizabeth Maitland7, Rugang Liu8,9,10, Qingzhen Hou1,2.
Abstract
Since 2019, the COVID-19 pandemic has resulted in sickness, hospitalizations, and deaths of the old and young and impacted global social and economy activities. Vaccination is one of the most important and efficient ways to protect against the COVID-19 virus. In a review of the literature on parents' decisions to vaccinate their children, we found that widespread vaccination was hampered by vaccine hesitancy, especially for children who play an important role in the coronavirus transmission in both family and school. To analyze parent vaccination decision-making for children, our review of the literature on parent attitudes to vaccinating children, identified the objective and subjective influencing factors in their vaccination decision. We found that the median rate of parents vaccinating their children against COVID-19 was 59.3% (IQR 48.60~73.90%). The factors influencing parents' attitudes towards child vaccination were heterogeneous, reflecting country-specific factors, but also displaying some similar trends across countries, such as the education level of parents. The leading reason in the child vaccination decision was to protect children, family and others; and the fear of side effects and safety was the most important reason in not vaccinating children. Our study informs government and health officials about appropriate vaccination policies and measures to improve the vaccination rate of children and makes specific recommendations on enhancing child vaccinate rates.Entities:
Keywords: COVID-19; acceptance; children; scoping review; vaccine hesitancy; willingness
Year: 2021 PMID: 34960221 PMCID: PMC8705627 DOI: 10.3390/vaccines9121476
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Search strategy algorithms.
| Search | Keywords |
|---|---|
| #1 | COVID-19 OR SARS-CoV-2 OR novel coronavirus OR coronavirus disease |
| #2 | vaccin* OR immunization |
| #3 | child* OR mother OR parents OR kid |
| #4 | Acceptance OR Agreement OR Willingness OR Refusal OR Resistance OR Confidence OR Hesitancy OR Antivaxx OR Antivaxxers OR Antivaccine OR Anti-vaccine |
| #5 | 2019 OR 2020 OR 2021 |
| #6 | #1 AND #2 AND #3 AND #4 AND #5 |
Figure 1PRISMA flow diagram of study selection.
Characteristic of Studies.
| First Author | Date of Publication | Sample Size | Participants | Parents’ Age | Parents’ Sex (Female) | Country | The Rate to Vaccinate Children against COVID-19 | The Rate to Vaccinate Parents Themselves against COVID-19 |
|---|---|---|---|---|---|---|---|---|
| Amiel A. Dror [ | 12 August 2020 | 1941 | Healthcare workers and general population | NA | NA | Israeli | 70% for general population | 75% for general population |
| Pınar Yılmazbaş [ | 29 September 2020 | 440 | Parents | 39.1 ± 6.4 | 70.4% | Turkey | 73.90% | NA |
| Luca Pierantoni [ | 12 October 2020 | 1812 families | Parents | NA | NA | Italy | Recommended (91.1%) | NA |
| Ran D. Goldman [ | 10 November 2020 | 1541 | Caregivers of child patients | 39.9 (median) (SD 7.58) | 71.97% | USA, Canada, Israel, Japan, Spain, and Switzerland | 65.20% | NA |
| Sadie Bell [ | 17 November 2020 | 1252 | Parents and guardians | 32.95 ± 4.565 | 95% | England | 89.10% | 90.10% |
| Büşra Akarsu [ | 5 December 2020 | 759 (232 had children between the ages of 0–18) | Adults | 32.41 ± 9.92 | 62.8% | Turkey | 38.4% | 49.7% |
| Emily A. Largent [ | 18 December 2020 | 2724 | Adults | >18 | 45.9% | USA | 48.60% | 61.40% |
| Ethan M. Scott [ | 12 February 2021 | 391 | Amish families | 38 (median) | 67% | USA | 24.30% | NA |
| Malia Skjefte [ | 1 March 2021 | 17871(5294 pregnant women) | Pregnant women and mothers | 34.4 ± 7.3 | 100% | Global | Given a 90% COVID-19 vaccine efficacy:69.2% | Given a 90% COVID-19 vaccine efficacy: |
| Jorge L. Alvarado-Socarras [ | 19 March 2021 | 1066 | Physicians | Inconsistent between groups | 47% | Colombia | 85.70% | 84.60% |
| Ronnie R. Marquez [ | 24 March 2021 | 99 | Caregivers of children receiving oral healthcare | 38.8 ± 9.1 | 83.5% | USA | 21.60% | 19.60% |
| Yigit, Metin [ | 1 April 2021 | 428 | The parents had children who were inpatients or outpatient | 39.7 ± 10.7 | 63.5% | Turkey | 28.9% (foreign vaccine) | 33.9% (foreign vaccine) |
| Qiang Wang and Shixin Xiu [ | 1 April 2021 | 3009 | Parents and HCWs from immunization clinics | 31.36 ± 4.46 | 74.6% | China | 59.30% | 51.20% |
| Marco Montalti [ | 10 April 2021 | 4993 | Parents/guardians | 40–49 majority (55.4%) | 76.6% | Italy | 60.40% | NA |
| Bridget J. Kelly [ | 12 April 2021 | 2279 (27% of respondents had children) | Adults | 50–64 majority (26%) | 52% | USA | 52.70% | 80.5% (male) |
| Erdem Gönüllü [ | 16 April 2021 | 506 (379 having a child) | Pediatrics | 41 ± 8 | 58% | Turkey | 75% | 83% |
| Jia Lu [ | 7 May 2021 | 3673 | Parents of the students | NA | 69.1% | China | 31.3~87.5% | 33.5%~89.7% |
| Stephanie Milan [ | 10 May 2021 | 240 | Mothers with a mental health history | 36.9 ± 7.42 | 100% | USA | 38.7% of mothers with a PTSD history were reluctant versus 25.8% of mothers without a PTSD history | Among mothers with a PTSD history, 40% were vaccine reluctant for themselves versus 23.9% of mothers without a PTSD history |
| Meltem Yılmazp [ | 16 May 2021 | 1035 | Parents | 30–39 years old (53.3%) | 77.8% | Turkey | 36.30% | 59.90% |
| Susanne Brandstetter [ | 17 May 2021 | 612 families | Parents | NA | 80% by mothers, and 10% by mothers and fathers together | Germany | 51% | 58% |
| Erin Hetherington [ | 21 May 2021 | 1321 | Parents | 42.2 ± 4.4 | 100% | Canada | 60.40% | NA |
| Linda Thunström [ | 4 June 2021 | 3133 | Adults | 45.63 ± 16.52 | 51.9% | USA | 19.7% (not intend to vaccinate) | 19.5% (not intend to vaccinate) |
| Yucheng Xu [ | 6 June 2021 | 4748 | Parents | 40.28 ± 5.08 | 76.0% | China | 72.70% | 74.80% |
| Yehong Zhou [ | 9 June 2021 | 1071 (at least have 747 children) | Adults and guardians of children who visited community health centers | 34.0 ± 7.4 | 76.5% | China | 85.30% | 88.60% |
| Zixin Wang [ | 17 June 2021 | 1332 | Parents who are healthcare workers | 31–40 majority (61.30%) | 89.4% | China | 44.50% | 72.40% |
| Kristine M. Ruggiero [ | 30 June 2021 | 427 | Parents of school-age children | NA | NA | NA | 49.45% | 44.17% |
| Kimberly K. Walker [ | 30 June 2021 | 25 | Mothers | 40–49 majority (60.00%) | 100% | USA | 16% | 16% |
| Andrea C. Carcelen [ | 6 July 2021 | 2400 | Parents who brought their children to vaccinate MR vaccine | NA | NA | Zambia | 92% | 66% |
| Aaron M Scherer [ | 16 July 2021 | 1022 | Parents and guardians | NA | 48.2% | USA | 55.50% | NA |
| Chloe A. Teasdale PhDab [ | 17 July 2021 | 2074 | Primary caregivers | 30–44 majority (66.88%) | 61.23% | USA | 50.30% | 49.40% |
| Kaidi He [ | 23 July 2021 | 252 | Parents of children patients | 30–44 majority (55.2%) | 83.3% | USA | NA | NA |
| Matthew Greenhawt [ | 24 February 2021 | 4855 | Adults | 30–39 majority (17.2%) | 50.2% | USA | 70.10% | 65.70% |
| Reem Al-Mulla [ | 18 June 2021 | 462 | QU students aged 18 years and above | 18–24 majority (32.7%) | 62.6% | QATAR | 46% (not intend to vaccinate) | 62.6% |
| Hatice İkiışık [ | 11 May 2021 | 384 | Adults ages of 20 to 85 | 43.3 ± 13.5 | 47.4% | Turkey | 10.40% | 54.70% |
| Flora Fedele [ | 7 June 2021 | 640 | Parents attending 4 pediatric practices | 35–50 majority (59.4%) | 74% | Italy | 17.20% | 26.50% |
Objective factors influencing parents’ decision to vaccinate children against COVID-19.
| Authors | Characteristic in Univariable Analysis | Characteristic in Multivariable Analysis | Positive/Negative |
|---|---|---|---|
| Luca Pierantoni [ | Either parent is a health-care worker | P | |
| Ran D. Goldman [ | Older children; | Older children | P |
| Child has chronic illness | N | ||
| Sadie Bell [ | Homemaker/unemployed (ref: working full-time); | Low Income < GBP 35,000 (ref: medium income GBP 35,000–84,999); | N |
| Büşra Akarsu [ | The increasing level of education; | P | |
| Emily A. Largent [ | Democrats (ref: Republicans and Independents); | P | |
| Black respondents (ref: Non-Black respondents) | N | ||
| Ethan M. Scott [ | Swartzentruber Amish | N | |
| Malia Skjefte [ | Master’s, professional school, doctoral degree (ref: college diploma or equivalent); | Have health insurance (ref: no health insurance) | P |
| Lower than 40 (ref: 40–65 years); | Lower than 40 (ref: 40–65 years); | N | |
| Yigit, Metin [ | Parents whose fear and anxiety levels were high | P | |
| As the education level increased, parents were less likely to | N | ||
| Qiang Wang & Shixin Xiu [ | College education or below (ref: Master’s Diploma or above); | College education or below (ref: Master’s Diploma or above) | P |
| Marco Montalti [ | Children aged 6–10 years (ref: >= 14); | N | |
| Bridget J. Kelly [ | Hispanic origin | P | |
| Female; | N | ||
| Stephanie Milan [ | Maternal education; | Maternal education; | P |
| African-American; | African-American; | N | |
| Meltem Yılmaz [ | Parents aged 40 or older (ref: 18–29); | Parents being healthcare workers | P |
| Susanne Brandstetter [ | Higher mother’ s age; | High educational level (university entrance level) (ref: Medium educational (10 years of schooling)) | P |
| High educational level (university entrance level) (ref: Medium educational (10 years of schooling)) | |||
| Risk group member in family, friends (yes) | Risk group member in family, friends (yes) | N | |
| Erin Hetherington [ | Participants with lower education, lower income | N | |
| Yucheng Xu [ | Male parents | P | |
| Parents with psychological distress | Parents with psychological distress | N | |
| Yehong Zhou [ | Participants with older individuals in their families; | Participants with older individuals in their families; | N |
| Zixin Wang [ | Worked in the infectious disease departments | P | |
| Those had middle rank technical job title | N | ||
| Kristine M. Ruggiero [ | High-risk child (chronic condition) | P | |
| Aaron M Scherer [ | Female; | N | |
| Chloe A. Teasdale [ | Asian parents (Ref: Non-Hispanic white) | P | |
| Female (Ref: male); | N | ||
| Kaidi He [ | Male sex; | P |
Subjective factors influencing parents’ decision to vaccinate children against COVID-19.
| Authors | Characteristic in Univariable Analysis | Characteristic in Multivariable Analysis | Positive/Negative |
|---|---|---|---|
| Luca Pierantoni [ | Fear of a new outbreak moderately (ref: Not at all/A little); | P | |
| Ran D. Goldman [ | Children that were up-to-date on their vaccines; | Children that were up-to-date on their vaccines; | P |
| Büşra Akarsu [ | Who got seasonal flu vaccine | Perceived risk of the virus/precautions | P |
| Malia Skjefte [ | Negative experiences with COVID-19; | Past acceptance and perceived safety/efficacy of other vaccines; | P |
| Yigit, Metin [ | Preference for the foreign vaccine for children was higher in males; | P | |
| Accept the domestic vaccine for their children | N | ||
| Marco Montalti [ | Relying on information found in the web/social media; | N | |
| Bridget J. Kelly [ | Received flu vaccine in past year; | P | |
| Stephanie Milan [ | Benevolent view of world; | P | |
| Institutional distrust | Institutional distrust | N | |
| Meltem Yılmaz [ | parents’ willingness and positive attitudes towards the COVID-19 vaccine; | Parents’ willingness to receive the vaccine and positive attitudes toward it; | P |
| Susanne Brandstetter [ | Confidence in one’s knowledge about safety measures (0–6); | Confidence in one’s knowledge about safety measures (0–6); | P |
| Perception that policy measures are exaggerated (0–4) | Perception that policy measures are exaggerated (0–4) | N | |
| Yehong Zhou [ | Participants with a self-reported history of influenza vaccination; | Participants with a self-reported history of influenza vaccination | P |
| Zixin Wang [ | Perceived higher vaccine efficacy and longer protection duration; | P | |
| Knowing some people who experienced serious side effects following COVID-19 vaccination | N | ||
| Kristine M. Ruggiero [ | Trust information about shots; | P | |
| Overall hesitancy about childhood shots; | N | ||
| Andrea C. Carcelen [ | Who believed COVID-19 vaccines would be safe; | P |
Figure 2Frequency of reasons of parents’ intention to vaccinate children against COVID-19: (a) frequency of reasons for vaccine acceptance; and (b) frequency of reasons for vaccine refusal.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. (PRISMA-ScR) Checklist.
| SECTION | ITEM | PRISMA-ScR CHECKLIST ITEM | REPORTED ON PAGE # |
|---|---|---|---|
| TITLE | |||
| Title | 1 | Identify the report as a scoping review. | 1 |
| ABSTRACT | |||
| Structured summary | 2 | Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives. | 1 |
| INTRODUCTION | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach. | 2 |
| Objectives | 4 | Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives. | 2 |
| METHODS | |||
| Protocol and registration | 5 | Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number. | 2 |
| Eligibility criteria | 6 | Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale. | 3 |
| Information sources * | 7 | Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed. | 3 |
| Search | 8 | Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. | 3 |
| Selection of sources of evidence † | 9 | State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. | 3 |
| Data charting process ‡ | 10 | Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators. | 3 |
| Data items | 11 | List and define all variables for which data were sought and any assumptions and simplifications made. | 3 |
| Critical appraisal of individual sources of evidence § | 12 | If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate). | NA |
| Synthesis of results | 13 | Describe the methods of handling and summarizing the data that were charted. | 3 |
| RESULTS | |||
| Selection of sources of evidence | 14 | Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram. | 4 |
| Characteristics of sources of evidence | 15 | For each source of evidence, present characteristics for which data were charted and provide the citations. | 5 |
| Critical appraisal within sources of evidence | 16 | If done, present data on critical appraisal of included sources of evidence (see item 12). | NA |
| Results of individual sources of evidence | 17 | For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives. | 7 |
| Synthesis of results | 18 | Summarize and/or present the charting results as they relate to the review questions and objectives. | 12 |
| DISCUSSION | |||
| Summary of evidence | 19 | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | 23 |
| Limitations | 20 | Discuss the limitations of the scoping review process. | 26 |
| Conclusions | 21 | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | 26 |
| FUNDING | |||
| Funding | 22 | Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review. | 27 |
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. * Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites. † A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote). ‡ The frameworks by Arksey and O’Malley (6), Levac and colleagues (7), and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting. § The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of “risk of bias” (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).